RISVODETINIB

Small molecule targets ABL1, ABL2 via inhibition

today NCT05424276 · Ph 2 NCT06641557 · Ph 1

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT06641557	Feb → Mar 2023	—	ABLi Therapeutics, Inc.	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT05424276	May 2023 → Oct 2024	Parkinson disease	ABLi Therapeutics, Inc.	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06644326 Comparator	Jun 2023 → Aug 2024	—	ABLi Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT04350177 Comparator	Feb 2021 → Oct 2022	Parkinson disease	ABLi Therapeutics, Inc.	Completed	No outcome recorded

Every value below carries the sentence it was read from. 6 sources stand behind the page.

Field	Value	Cited text
Known as	RISVODETINIB	ChEMBL registry synonym — accepted as the source's own label CHEMBL5314481 ↗
Known as	IkT-148009	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04350177 ↗ 3 NCT06644326 ↗ NCT06641557 ↗ NCT05424276 ↗
Known as	IKT148009 SUCCINATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL5314481 ↗
Known as	RISVODETINIB SUCCINATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL5314481 ↗
Action	Inhibit	“selective inhibitor of the nonreceptor Abl kinases” PMID 41721133 ↗ Feb 2026
Modality	Small molecule	— CHEMBL5314481 ↗
Route	Oral	“Oral administration gelatin capsule” NCT04350177 ↗
Target	ABL1	“selective inhibitor of the nonreceptor Abl kinases c-Abl1 and c-Abl2/Arg” PMID 41721133 ↗ Feb 2026
Target	ABL2	“selective inhibitor of the nonreceptor Abl kinases c-Abl1 and c-Abl2/Arg” PMID 41721133 ↗ Feb 2026